PYC Therapeutics (ASX:PYC) Debt-to-Asset : 0.01 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PYC PYC Therapeutics Ltd ASX:PYC
29 GF Score
Price A$2.07
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Debt-to-Asset?

PYC Therapeutics ASX:PYC -5.91% 29 Debt-to-Asset is 0.01 as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

PYC Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.39 Mil. PYC Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.44 Mil. PYC Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was A$159.13 Mil. PYC Therapeutics's debt to asset for the quarter that ended in Dec. 2025 was 0.01.

PYC Therapeutics  (ASX:PYC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

PYC Therapeutics Debt-to-Asset Related Terms

PYC Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics Debt-to-Asset Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 0.01 0.01 0.01

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.02 0.01 0.01

ASX:PYC vs VRTX, REGN, RVMD: Debt-to-Asset Comparison

For the Biotechnology subindustry, PYC Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PYC Therapeutics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's Debt-to-Asset falls into.


ASX:PYC
29GF Score
PYC Therapeutics Ltd ASX:PYC
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

PYC Therapeutics's Debt-to-Asset for the fiscal year that ended in Jun. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.399 + 0.625) / 183.279
=0.01

PYC Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.39 + 0.437) / 159.13
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.01 mean?
PYC Therapeutics (ASX:PYC) has a Debt-to-Asset of 0.01 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on PYC Therapeutics and its competitors.
Is PYC Therapeutics' Debt-to-Asset too high?
PYC Therapeutics' current Debt-to-Asset is 0.01. Overall, PYC Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Debt-to-Asset compare to VRTX and REGN?
PYC Therapeutics' Debt-to-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current Debt-to-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Debt-to-Asset of 0.01. The current Debt-to-Asset is 0.01. PYC Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Debt-to-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
29GF Score

Get the complete analysis for ASX:PYC

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.07
Price